Hyperactivity - Mental Focus
- Manufacturer
- Newton Laboratories, Inc.
- Effective date
- 2011-06-01
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:05:11
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Hyperactivity - Mental Focus Formulated for symptoms associated with adult attention-deficit and hyperactivity disorders, for emotional balance and mental focus.
DOSAGE & ADMINISTRATION SECTION
Directions: Ages 12 and up, take 6 pellets orally one to four times daily or as directed by a healthcare professional.
ACTIVE INGREDIENT SECTION
Adrenalinum 20x, Tarentula cubensis 20x, Aconitum nap. 15x, Arg. nit. 15x, Arsenicum alb. 15x, Baptisia 15x, Chamomilla 15x, Cypripedium 15x, Digitalis 15x, Gelsemium 15x, Humulus 15x, Ignatia 15x, Impatiens glandulifera flos 15x, Iodium 15x, Lachesis 15x, Lycopodium 15x, Nat. mur. 15x, Nux vom.15x, Scutellaria lateriflora 15x, Staphysag. 15x, Stramonium 15x, Theridion 15x, Echinacea 8x, Gingko 8x, Hypericum 8x, Passiflora 8x, Echinacea 3x, Gingko 3x, Hypericum 3x, Passiflora 3x.
PURPOSE SECTION
Formulated for symptoms associated with adult attention-deficit and hyperactivity disorders, and support for emotional balance and mental focus.
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Gluten-free, non-GMO, beet-derived sucrose pellets.
QUESTIONS? SECTION
www.newtonlabs.net Newton Laboratories, Inc. FDA Est # 1051203 - Conyers, GA 30012
Questions? 1.800.448.7256
WARNINGS SECTION
Warning: Do not use if tamper - evident seal is broken or missing. Consult a licensed healthcare professional if pregnant, nursing or if symptoms worsen or persist for more than a few days. Keep out of reach of children.
PREGNANCY OR BREAST FEEDING SECTION
Consult a licensed healthcare professional if pregnant, nursing or if symptoms worsen or persist for more than a few days.
KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children.
PACKAGE LABEL
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 55714-4541-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-84ac-f424-e053-dadaa90a57ce | Hyperactivity - Mental Focus |
| 55714-4541-2 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-84ac-f424-e053-dadaa90a57ce | Hyperactivity - Mental Focus |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 55714-4541-1 | Hyperactivity - Mental Focus | 28.35 g in 1 BOTTLE, GLASS | PELLET | 28.35 | 1 | |
| 55714-4541-2 | Hyperactivity - Mental Focus | 56.7 g in 1 BOTTLE, GLASS | PELLET | 56.7 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 55714-4541 | HYPERACTIVITY - MENTAL FOCUS (ADRENALINUM, TARENTULA CUBENSIS, ACONITUM NAP., ARG. NIT., ARSENICUM ALB., BAPTISIA, CHAMOMILLA, CYPRIPEDIUM, DIGITALIS, GELSEMIUM, HUMULUS, IGNATIA, IMPATIENS GLANDULIFERA FLOS, IODIUM, LACHESIS, LYCOPODIUM, NAT. MUR., NUX VOM., SCUTELLARIA LATERIFLORA, STAPHYSAG., STRAMONIUM, THERIDION, ECHINACEA, GINGKO, HYPERICUM, PASSIFLORA) PELLET [NEWTON LABORATORIES, INC.] | 1 | Legacy NDC, 2 package rows | 20131112_7f2a7a7b-d750-623a-74e0-f96b8d41cbb8.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Aconitum Napellus | ACTIVE INGREDIENT | U0NQ8555JD | 1 | |
| Arsenic Trioxide | ACTIVE INGREDIENT | S7V92P67HO | 1 | |
| Baptisia Tinctoria | ACTIVE INGREDIENT | 5K1UO2888Y | 1 | |
| Citharacanthus Spinicrus | ACTIVE INGREDIENT | 3Y5X6RT823 | 1 | |
| Cypripedium Parvifolum Root | ACTIVE INGREDIENT | 21Y9GZ1LZA | 1 | |
| Datura Stramonium | ACTIVE INGREDIENT | G6W4F0V8Z3 | 1 | |
| Delphinium Staphisagria Seed | ACTIVE INGREDIENT | 00543AP1JV | 1 | |
| Digitalis | ACTIVE INGREDIENT | F1T8QT9U8B | 1 | |
| Echinacea, Unspecified | ACTIVE INGREDIENT | 4N9P6CC1DX | 1 | |
| Epinephrine | ACTIVE INGREDIENT | YKH834O4BH | 1 | |
| Gelsemium Sempervirens Root | ACTIVE INGREDIENT | 639KR60Q1Q | 1 | |
| Ginkgo | ACTIVE INGREDIENT | 19FUJ2C58T | 1 | |
| Hops | ACTIVE INGREDIENT | 01G73H6H83 | 1 | |
| Hypericum Perforatum | ACTIVE INGREDIENT | XK4IUX8MNB | 1 | |
| Impatiens Glandulifera Flower | ACTIVE INGREDIENT | AJU5O1A5ZV | 1 | |
| Iodine | ACTIVE INGREDIENT | 9679TC07X4 | 1 | |
| Lachesis Muta Venom | ACTIVE INGREDIENT | VSW71SS07I | 1 | |
| Lycopodium Clavatum Spore | ACTIVE INGREDIENT | C88X29Y479 | 1 | |
| Matricaria Recutita | ACTIVE INGREDIENT | G0R4UBI2ZZ | 1 | |
| Passiflora Incarnata Flowering Top | ACTIVE INGREDIENT | CLF5YFS11O | 1 | |
| Scutellaria Lateriflora | ACTIVE INGREDIENT | 7BP4DH5PDC | 1 | |
| Silver Nitrate | ACTIVE INGREDIENT | 95IT3W8JZE | 1 | |
| Sodium Chloride | ACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| Strychnos Ignatii Seed | ACTIVE INGREDIENT | 1NM3M2487K | 1 | |
| Strychnos Nux-vomica Seed | ACTIVE INGREDIENT | 269XH13919 | 1 | |
| Theridion Curassavicum | ACTIVE INGREDIENT | 9Z8D3HEM8L | 1 | |
| Aconitum Napellus | ACTIVE MOIETY | U0NQ8555JD | 1 | |
| Arsenic Cation (3+) | ACTIVE MOIETY | C96613F5AV | 1 | |
| Baptisia Tinctoria | ACTIVE MOIETY | 5K1UO2888Y | 1 | |
| Chloride Ion | ACTIVE MOIETY | Q32ZN48698 | 1 | |
| Citharacanthus Spinicrus | ACTIVE MOIETY | 3Y5X6RT823 | 1 | |
| Cypripedium Parvifolum Root | ACTIVE MOIETY | 21Y9GZ1LZA | 1 | |
| Datura Stramonium | ACTIVE MOIETY | G6W4F0V8Z3 | 1 | |
| Delphinium Staphisagria Seed | ACTIVE MOIETY | 00543AP1JV | 1 | |
| Digitalis | ACTIVE MOIETY | F1T8QT9U8B | 1 | |
| Echinacea, Unspecified | ACTIVE MOIETY | 4N9P6CC1DX | 1 | |
| Epinephrine | ACTIVE MOIETY | YKH834O4BH | 1 | |
| Gelsemium Sempervirens Root | ACTIVE MOIETY | 639KR60Q1Q | 1 | |
| Ginkgo | ACTIVE MOIETY | 19FUJ2C58T | 1 | |
| Hops | ACTIVE MOIETY | 01G73H6H83 | 1 | |
| Hypericum Perforatum | ACTIVE MOIETY | XK4IUX8MNB | 1 | |
| Impatiens Glandulifera Flower | ACTIVE MOIETY | AJU5O1A5ZV | 1 | |
| Iodine | ACTIVE MOIETY | 9679TC07X4 | 1 | |
| Lachesis Muta Venom | ACTIVE MOIETY | VSW71SS07I | 1 | |
| Lycopodium Clavatum Spore | ACTIVE MOIETY | C88X29Y479 | 1 | |
| Matricaria Recutita | ACTIVE MOIETY | G0R4UBI2ZZ | 1 | |
| Passiflora Incarnata Flowering Top | ACTIVE MOIETY | CLF5YFS11O | 1 | |
| Scutellaria Lateriflora | ACTIVE MOIETY | 7BP4DH5PDC | 1 | |
| Silver Cation | ACTIVE MOIETY | 57N7B0K90A | 1 | |
| Strychnos Ignatii Seed | ACTIVE MOIETY | 1NM3M2487K | 1 | |
| Strychnos Nux-vomica Seed | ACTIVE MOIETY | 269XH13919 | 1 | |
| Theridion Curassavicum | ACTIVE MOIETY | 9Z8D3HEM8L | 1 | |
| Sucrose | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Hyperactivity - Mental Focus
- Adrenalinum, Tarentula cubensis, Aconitum nap., Arg. nit., Arsenicum alb., Baptisia, Chamomilla, Cypripedium, Digitalis, Gelsemium, Humulus, Ignatia, Impatiens glandulifera flos, Iodium, Lachesis, Lycopodium, Nat. mur., Nux vom., Scutellaria lateriflora, Staphysag., Stramonium, Theridion, Echinacea, Gingko, Hypericum, Passiflora
- Epinephrine
- Citharacanthus Spinicrus
- Aconitum Napellus
- Silver Nitrate
- Silver Cation
- Arsenic Trioxide
- Arsenic Cation (3+)
- Baptisia Tinctoria
- Matricaria Recutita
- Cypripedium Parvifolum Root
- Digitalis
- Gelsemium Sempervirens Root
- Hops
- Strychnos Ignatii Seed
- Impatiens Glandulifera Flower
- Iodine
- Lachesis Muta Venom
- Lycopodium Clavatum Spore
- Sodium Chloride
- Chloride Ion
- Strychnos Nux-vomica Seed
- Scutellaria Lateriflora
- Delphinium Staphisagria Seed
- Datura Stramonium
- Theridion Curassavicum
- Echinacea, Unspecified
- Ginkgo
- Hypericum Perforatum
- Passiflora Incarnata Flowering Top
- Sucrose
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 55714-4541 | 55714-4541-1, 55714-4541-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sucrose | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| Sucrose | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| Sucrose | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| Sucrose | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| Sucrose | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| Sucrose | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| Sucrose | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| Sucrose | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| Sucrose | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| Sucrose | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| Sucrose | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| Sucrose | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| Sucrose | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| Sucrose | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| Sucrose | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| Sucrose | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| Sucrose | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| Sucrose | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| Sucrose | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| Sucrose | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| Sucrose | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| Sucrose | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| Sucrose | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| Sucrose | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| Sucrose | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| Sucrose | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 47c80df1-280e-47d6-e72c-6debd31bd812 | 7f2a7a7b-d750-623a-74e0-f96b8d41cbb8 | 2011-06-01 | Warnings | 47c80df1-280e-47d6-e72c-6debd31bd812 7f2a7a7b-d750-623a-74e0-f96b8d41cbb8 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
